Literature DB >> 15275563

Recurrent cutaneous leishmaniasis: a role for persistent parasites?

T Aebischer1.   

Abstract

Leishmaniosis is, with increasing frequency, reported as an opportunistic infection of immunosuppressed individuals. Re-activation of persistent parasites may be responsible for the disease in a number of these patients. Here, Toni Aebischer reviews some of the evidence for the implication of persistent Leishmania infections in recurrent disease with the emphasis on cutaneous leishmoniasis in humans and in the mouse model. The data suggest that parasite persistence is a common feature in Leishmania infections. The availability of on excellent laboratory model provides on opportunity to study this phenomenon in detail. The findings of these analyses are likely to be important for the identification of people at risk of developing recurrent disease and for the assessment of new therapies for relapsing leishmaniasis and might also have implications for the design of a future anti-Leishmania vaccine.

Entities:  

Year:  1994        PMID: 15275563     DOI: 10.1016/0169-4758(94)90353-0

Source DB:  PubMed          Journal:  Parasitol Today        ISSN: 0169-4758


  18 in total

Review 1.  Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies.

Authors:  Ifeoma Okwor; Jude Uzonna
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 2.  Cutaneous leishmaniasis: a model for analysis of the immunoregulation by accessory cells.

Authors:  H Moll; U Ritter; S Flohé; K Erb; C Bauer; C Blank
Journal:  Med Microbiol Immunol       Date:  1996-02       Impact factor: 3.402

3.  Simultaneous infection with Leishmania (Viannia) braziliensis and L. (V.) lainsoni in a Peruvian patient with cutaneous leishmaniasis.

Authors:  Nicolas Veland; Braulio Mark Valencia; Milena Alba; Vanessa Adaui; Alejandro Llanos-Cuentas; Jorge Arevalo; Andrea K Boggild
Journal:  Am J Trop Med Hyg       Date:  2013-02-04       Impact factor: 2.345

4.  Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy.

Authors:  Rafael de La Rosa; Juan A Pineda; Juan Delgado; Juan Macías; Francisco Morillas; José A Mira; Armando Sánchez-Quijano; Manuel Leal; Eduardo Lissen
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

5.  Continual renewal and replication of persistent Leishmania major parasites in concomitantly immune hosts.

Authors:  Michael A Mandell; Stephen M Beverley
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

6.  Real-time PCR for detection and quantitation of leishmania in mouse tissues.

Authors:  Luc Nicolas; Eric Prina; Thierry Lang; Geneviève Milon
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

7.  Subunit vaccination of mice against new world cutaneous leishmaniasis: comparison of three proteins expressed in amastigotes and six adjuvants.

Authors:  T Aebischer; M Wolfram; S I Patzer; T Ilg; M Wiese; P Overath
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

8.  Leishmania major reaches distant cutaneous sites where it persists transiently while persisting durably in the primary dermal site and its draining lymph node: a study with laboratory mice.

Authors:  L Nicolas; S Sidjanski; J H Colle; G Milon
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

9.  Cutaneous leishmaniasis in the Peruvian Andes: an epidemiological study of infection and immunity.

Authors:  C R Davies; E A Llanos-Cuentas; S D Pyke; C Dye
Journal:  Epidemiol Infect       Date:  1995-04       Impact factor: 2.451

Review 10.  The immunology of Leishmania/HIV co-infection.

Authors:  Ifeoma Okwor; Jude Eze Uzonna
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.